Literature DB >> 18346207

A novel calcium-binding protein is associated with tau proteins in tauopathy.

Irving E Vega1, Edwin E Traverso, Yancy Ferrer-Acosta, Eduardo Matos, Migdalisel Colon, John Gonzalez, Dennis Dickson, Michael Hutton, Jada Lewis, Shu H Yen.   

Abstract

Tauopathies are a group of neurological disorders characterized by the presence of intraneuronal hyperphosphorylated and filamentous tau. Mutations in the tau gene have been found in kindred with tauopathy. The expression of the human tau mutant in transgenic mice induced neurodegeneration, indicating that tau plays a central pathological role. However, the molecular mechanism leading to tau-mediated neurodegeneration is poorly understood. To gain insights into the role that tau plays in neurodegeneration, human tau proteins were immunoprecipitated from brain lysates of the tauopathy mouse model JNPL3, which develops neurodegeneration in age-dependent manner. In the present work, a novel EF-hand domain-containing protein was found associated with tau proteins in brain lysate of 12-month-old JNPL3 mice. The association between tau proteins and the novel identified protein appears to be induced by the neurodegeneration process as these two proteins were not found associated in young JNPL3 mice. Consistently, the novel protein co-purified with the pathological sarkosyl insoluble tau in terminally ill JNPL3 mice. Calcium-binding assays demonstrated that this protein binds calcium effectively. Finally, the association between tau and the novel calcium-binding protein is conserved in human and enriched in Alzheimer's disease brain. Taken together, the identification of a novel calcium-binding protein associated with tau protein in terminally ill tauopathy mouse model and its confirmation in human brain lysate suggests that this association may play an important physiological and/or pathological role.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346207      PMCID: PMC3696493          DOI: 10.1111/j.1471-4159.2008.05339.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.

Authors:  Tudor A Fulga; Ilan Elson-Schwab; Vikram Khurana; Michelle L Steinhilb; Tara L Spires; Bradley T Hyman; Mel B Feany
Journal:  Nat Cell Biol       Date:  2006-12-24       Impact factor: 28.824

2.  Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

Authors:  Zdenek Berger; Hanno Roder; Amanda Hanna; Aaron Carlson; Vijayaraghavan Rangachari; Mei Yue; Zbigniew Wszolek; Karen Ashe; Joshua Knight; Dennis Dickson; Cathy Andorfer; Terrone L Rosenberry; Jada Lewis; Mike Hutton; Christopher Janus
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

3.  Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.

Authors:  Jian-Zhi Wang; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

4.  Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations.

Authors:  Huiping Tu; Omar Nelson; Arseny Bezprozvanny; Zhengnan Wang; Sheu-Fen Lee; Yi-Heng Hao; Lutgarde Serneels; Bart De Strooper; Gang Yu; Ilya Bezprozvanny
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

5.  The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.

Authors:  Chad A Dickey; Adeela Kamal; Karen Lundgren; Natalia Klosak; Rachel M Bailey; Judith Dunmore; Peter Ash; Sareh Shoraka; Jelena Zlatkovic; Christopher B Eckman; Cam Patterson; Dennis W Dickson; N Stanley Nahman; Michael Hutton; Francis Burrows; Leonard Petrucelli
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

6.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

Review 7.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders.

Authors:  Carlo Ballatore; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2007-09       Impact factor: 34.870

Review 8.  Tauopathies.

Authors:  F Hernández; J Avila
Journal:  Cell Mol Life Sci       Date:  2007-09       Impact factor: 9.261

Review 9.  A hundred years of Alzheimer's disease research.

Authors:  John Hardy
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

Review 10.  Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store.

Authors:  Olivier Thibault; John C Gant; Philip W Landfield
Journal:  Aging Cell       Date:  2007-04-26       Impact factor: 9.304

View more
  36 in total

1.  Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration.

Authors:  Héctor J De Jesús-Cortés; Carlos J Nogueras-Ortiz; Marla Gearing; Steven E Arnold; Irving E Vega
Journal:  Neuroreport       Date:  2012-11-14       Impact factor: 1.837

2.  Functional and structural analysis of the conserved EFhd2 protein.

Authors:  Yancy Ferrer-Acosta; Eva N Rodríguez Cruz; Ana del C Vaquer; Irving E Vega
Journal:  Protein Pept Lett       Date:  2013-05       Impact factor: 1.890

3.  Cdk5 phosphorylation of EFhd2 at S74 affects its calcium binding activity.

Authors:  Edwin Vázquez-Rosa; Eva N Rodríguez-Cruz; Sybelle Serrano; Lucelenie Rodríguez-Laureano; Irving E Vega
Journal:  Protein Sci       Date:  2014-06-18       Impact factor: 6.725

4.  Monoclonal antibodies to discriminate the EF hand containing calcium binding adaptor proteins EFhd1 and EFhd2.

Authors:  Sebastian Brachs; Christiane Lang; Rolf Buslei; Pavitra Purohit; Barbara Fürnrohr; Hubert Kalbacher; Hans-Martin Jäck; Dirk Mielenz
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-08

5.  EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity.

Authors:  Michael Peled; Matthew A Dragovich; Kieran Adam; Marianne Strazza; Anna S Tocheva; Irving E Vega; Adam Mor
Journal:  J Immunol       Date:  2018-10-01       Impact factor: 5.422

6.  Blockade of NR2A-containing NMDA receptors induces Tau phosphorylation in rat hippocampal slices.

Authors:  Julie Allyson; Eve Dontigny; Yves Auberson; Michel Cyr; Guy Massicotte
Journal:  Neural Plast       Date:  2010-05-20       Impact factor: 3.599

7.  The S100B/RAGE Axis in Alzheimer's Disease.

Authors:  Estelle Leclerc; Emmanuel Sturchler; Stefan W Vetter
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-21

8.  EFhd2 is a novel amyloid protein associated with pathological tau in Alzheimer's disease.

Authors:  Yancy Ferrer-Acosta; Eva N Rodríguez-Cruz; François Orange; Hector De Jesús-Cortés; Bismark Madera; Jaime Vaquer-Alicea; Juan Ballester; Maxime J-F Guinel; George S Bloom; Irving E Vega
Journal:  J Neurochem       Date:  2013-02-14       Impact factor: 5.372

9.  Swiprosin-1 deficiency impairs macrophage immune response of septic mice.

Authors:  Su Zhang; Ye Tu; Yi-Ming Sun; Ya Li; Rong-Mei Wang; Yongbing Cao; Ling Li; Li-Chao Zhang; Zhi-Bin Wang
Journal:  JCI Insight       Date:  2018-02-08

10.  Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease.

Authors:  Irving E Vega; Andrew Umstead; Cassandra M Wygant; John S Beck; Scott E Counts
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.